Eliminating H2RAs From Paclitaxel Premedication Does Not Increase Infusion Reactions
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Diagnosis & Disease Information
Antibody-Drug Conjugates Pose Risk of Ocular Adverse Effects
Pharmaceutical experts review ocular adverse effects related to antibody-drug conjugates.
Dexamethasone No Longer Needed as an Antiemetic, Doc Says
Phase 3 trial results suggest that it’s time to move away from using dexamethasone as an antiemetic, said Venkatraman Radhakrishnan, MD.
Aerobic Exercise Cuts Chemotherapy-Induced Peripheral Neuropathy Symptoms
Aerobic exercise can improve self-reported chemotherapy-induced peripheral neuropathy among patients with ovarian cancer, a study suggests.
Mood, Distress Outcomes Improved With Music During Chemotherapy
Listening to music during chemotherapy infusions improved cancer patients’ moods and reduced levels of distress in a recent study.
Aprepitant Better Than Desloratadine for TKI-Induced Pruritus
A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.
High-Dose Dexamethasone Not Recommended for Dyspnea in Cancer Patients
The mean change in dyspnea intensity was no different between patients who received dexamethasone and those who received placebo.
Mepitel Film Reduces Radiation Dermatitis in Breast Cancer Patients
Mepitel Film reduced the rate of grade 2-3 radiation dermatitis in patients with breast cancer.
Oncodental Team Established to Prevent MBI-CLABSIs in Children With Cancer
Researchers sought to determine whether creating a pediatric oncodental team would help prevent MBI-CLABSIs in high-risk children with cancer.
Pedmark Now Available to Reduce Risk of Cisplatin-Induced Hearing Loss in Children
Pedmark is the first FDA-approved therapy indicated to reduce the risk of cisplatin-induced hearing loss in children.
- Loading...
Loading...
Next post in Pediatric Cancer
Loading... 
Loading...